Stock Analysis, Dividends, Split History

RMTI / Rockwell Medical, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)255.22
Enterprise Value ($M)216.71
Book Value ($M)16.89
Book Value / Share0.33
Price / Book12.94
NCAV ($M)11.00
NCAV / Share0.21
Price / NCAV19.86
Share Statistics
Common Shares Outstanding 51,768,424
Common Stock Shares Outstanding 51,768,424
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.79
Return on Assets (ROA)-0.31
Return on Equity (ROE)-0.49
Balance Sheet (mrq) ($M)
Quick Ratio2.76
Current Ratio3.16
Income Statement (mra) ($M)
Sales Revenue Goods Net57,300,281.00
Operating Income-25.92
Net Income-25.92
Earnings Per Share Diluted-0.51
Earnings Per Share Basic-0.51
Cash Flow Statement (mra) ($M)
Cash From Operations-21.11
Cash from Investing14.50
Cash from Financing14.50
Identifiers and Descriptors
Central Index Key (CIK)1041024
Related CUSIPS
774374902 774374952

Split History

Stock splits are used by Rockwell Medical, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

The Top 10 Wildest Campaigns Of 2018; Starboard's Stake In Symante

2018-08-17 valuewalk
This week’s column is a continuation of our 10 “wildest campaigns” of 2018. Find the first part here. (122-1)

Rockwell Medical's (RMTI) CEO Benjamin Wolin on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2018 Results Earnings Conference Call August 14, 2018 5:00 PM ET (114-1)

Whistleblower Complaint, Investigation Demands and Claimed Breaches of Fiduciary Duty Are Part of...

2018-07-11 biospace
The lawsuit and counter-lawsuits over the ouster of Rockwell Medical ’s chief executive officer can be convoluted to follow, particularly as allegations are thrown around. BioSpace has put together a synopsis of the events. (107-0)

Former Rockwell Medical CEO Files Lawsuit, Company Files Counter Lawsuit in Ongoing Legal Battle

2018-07-10 biospace
Legal battles are continuing between the Rockwell Medical Board of Directors and two senior executives who were fired earlier this year. The two executives were fired over claims of mismanagement of the company, the board said. (107-0)

Rockwell Medical CEO Conflict with Board of Directors Over Firing

2018-05-25 biospace
A tangled web has been woven at Michigan-based Rockwell Medical . The board of directors has fired the chief executive officer and chief financial officer. However, the ousted executives contend their firings were unlawful and also raised the specter of financial hijinks among some members of the board. (7-4)

CUSIP: 774374102